By enGenes Biotech…
Subscribe to Supplier
Subscribe to Supplier
Focus on hi-tech continuous biological production at Bioprocessing Summit in Barcelona
Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech will be a prominent presence at the BioProcess Summit Europe in Barcelona, later this month.
The enGenes team under the leadership of its CEO Dr. Juergen Mairhofer will make two contributions to the conference program, highlighting different aspects of its pioneering work towards continuous production of biotechnological products, as part of the European ECOnti Project.
ECOnti explained
On the final day of the Summit, Dr. Mairhofer will make a plenary presentation on the project, ‘ECOnti—Accelerated, Low Ecological Footprint, Manufacturing Platform for Continuous Production of Biotechnological Products’ as part of the conference’s Intensified and Continuous Processing track (March 20, 11:35 hrs.).
His address will show how the project consortium that includes enGenes, along with Novasign GmbH, Qubicon AG, SimVantage GmbH, Tosoh, and Vienna’s BOKU University of Natural Resources and Life Sciences, was created to advance continuous manufacturing of biological products using Escherichia coli (E. coli) with a capacity of up to 10 liters per batch.
Advanced technologies
The project combines advanced production methods with leveraged high end IT predictive control and conducting detailed economic modelling to achieve an overall ECOnti goal of proving continuous manufacturing as a framework that is more sustainable and cost-effective than conventional batch-based approaches.
Dr. Mairhofer will show how proprietary enGenes technologies, such as the -eXcess™ platform for enhanced yield decoupled production of recombinant proteins, along with the -eXchange™ platform for antibiotic-free and resistance marker-free manufacturing of recombinant proteins and high-quality plasmid DNA, have provided key pieces of the puzzle.
Novel E. coli strain
The enGenes team in Barcelona will also include senior scientist Dr. Natalia Danielewicz, who will present a poster that highlights enGenes contributions to the ECOnti project, including its recent engineering of a new strain of E. coli that is optimized to support end-to-end continuous manufacturing of biomolecules.
Dr. Natalia Danielewicz is hoping to engage in detailed discussions on these topics as part of the conference poster session.
About enGenes Biotech
enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading-edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of the current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.
enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes-eXpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-eXpress™, has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.
enGenes Biotech offers development and manufacturing services tailored to the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.
Find out more at: https://www.engenes.cc
About Bioprocessing Summit Europe 2025
First staged in 2017, the annual Bioprocessing Summit Europe focuses on implementing semi- and fully continuous processing in upstream (USP) and downstream processing (DSP) for clinical and commercial uses.
The Summit brings together more than 750 professionals from the upstream, downstream, bioproduction, and analytical sectors in industry and academia to advance the manufacture, quality, and control of next generation biologics and genetic therapies.
The 8th Bioprocessing Europe Summit will be a three-day event opening March 18 at the InterContinental Barcelona hotel and convention center. The meeting will feature 14 distinct conference tracks exploring topics ranging from cell culture and downstream processing to analytics, and the latest in cell, gene, and RNA therapies. For 2025, a further track will focus on Process Modelling and Digitalization.
The event is organized by Cambridge Healthtech Institute with further information at: https://www.bioprocessingeurope.com.
Resources
Click on enGenes Biotech’s continuous microbial protein expression and purification to learn more.
Click on ECOnti – Accelerated, Low Ecological Footprint, Manufacturing to download factsheet on project.
Dr. Juergen Mairhofer, CEO and co-founder, enGenes Biotech GmbH.
Related Articles
